News in Transplantation
前言 为了鼓励更多中青年医生在移植领域开展临床相关的研究，为临床探索更多优化器官质量或者促进临床转归的方法，从而帮助更多移植受者实现长期存活的目标，健耕医药成立了“启明星项目”。
启明星项目是针对器官移植临床研究的评比活动，面向中青年医生。本次为第三届启明星评选。我们诚邀肝移植领域的青年才俊来参与肝脏机械灌注或肝脏GcfDNA相关的临床课题研究。
报名方式 点击“阅读原文”报名， 我们会在7个工作日内与您联系。 报名截止日期
6月30日
扫码关注我们 微信号｜Tx新方案 健耕医药，专注移植产业
The company was founded in 2004 with a registered capital of RMB 70.4 million and 194 employees worldwide, including 46 R&D staff members. The company focuses on organ transplantation as a provider of medical products and professional services for the global market around the entire transplant process. Focusing on the needs of organ transplantation surgeons and patients, we provides medical devices and professional services related to organ transplantation, mainly involving products for the preservation, transportation, evaluation and repair of transplanted organs and in vitro diagnostic reagents for individualized and precise diagnosis of transplant patients, which are exported to about 46 countries and regions worldwide.
